Relay Therapeutics reported a Phase 2 efficacy signal for zovegalisib (RLY-2608) in PIK3CA-driven vascular anomalies, a group of rare disorders with limited approved options. The company said the therapy achieved a 60% volumetric response in patients enrolled in the trial, exceeding expectations. The result positions the isoform-selective PI3Kα inhibitor beyond its broader oncology context and suggests additional commercial runway if subsequent studies corroborate the volumetric response measure. The company also provided a lens on how the vascular anomalies readout could reshape the development priorities for zovegalisib. Separately, another update in the materials bundle reiterated the same signal and discussed market forecasts for potential peak revenues in the vascular anomalies segment.